An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137 – A successful approach.

MLA

Petzoldt, Christine, et al. “An Example of How to Handle Amorphous Fractions in API during Early Pharmaceutical Development: SAR114137 – A Successful Approach.” European Journal of Pharmaceutics & Biopharmaceutics, vol. 86, no. 3, Apr. 2014, pp. 337–50. EBSCOhost, https://doi.org/10.1016/j.ejpb.2013.09.015.

APA

Petzoldt, C., Bley, O., Byard, S. J., Andert, D., Baumgartner, B., Nagel, N., Tappertzhofen, C., & Feth, M. P. (2014). An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137 – A successful approach. European Journal of Pharmaceutics & Biopharmaceutics, 86(3), 337–350. https://doi.org/10.1016/j.ejpb.2013.09.015

Chicago

Petzoldt, Christine, Oliver Bley, Stephen J. Byard, Doris Andert, Bruno Baumgartner, Norbert Nagel, Christoph Tappertzhofen, and Martin Philipp Feth. 2014. “An Example of How to Handle Amorphous Fractions in API during Early Pharmaceutical Development: SAR114137 – A Successful Approach.” European Journal of Pharmaceutics & Biopharmaceutics 86 (3): 337–50. doi:10.1016/j.ejpb.2013.09.015.